Clinical TrialMay 21, 2026, 05:02 PM
Legend Biotech to Present New Data for LB2102 & CARVYKTI at ASCO 2026
AI Summary
Legend Biotech announced it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This includes preliminary Phase 1 data for LB2102, its investigational CAR-T therapy for relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC), and new data on CARVYKTI® (ciltacabtagene autoleucel) from the CARTITUDE program. The company will also host a live webcast event for investors on May 31, 2026, to discuss CARVYKTI's impact on multiple myeloma treatment.
Key Highlights
- Preliminary Phase 1 data for LB2102 (DLL3-targeted CAR-T) in relapsed/refractory SCLC/LCNEC to be presented.
- New data on CARVYKTI® from CARTITUDE-4 study, including cytogenetic subgroup analysis, to be presented as a poster.
- Multi-study analysis on immune effector cell-associated enterocolitis (IEC-EC) from CARVYKTI® trials to be presented.
- Investor relations event and webcast on May 31, 2026, at 6:15 PM CT during ASCO Annual Meeting.
- LB2102 expands CAR-T therapies into solid tumors; Novartis holds exclusive worldwide license for DLL3-targeted therapies.
- CARVYKTI® is commercially available in 18 countries and has treated over 10,000 patients to date.
Price Impact
More from LEGN